Compare Gilead Sciences, Inc. (GILD) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Paycom Software Inc — how do they compare? Gilead Sciences, Inc. trades at $136.36 (market cap $163.51B), while Paycom Software Inc trades at $149.78 (market cap $6.75B). The key difference: Gilead Sciences, Inc. is far larger — about 24.2× Paycom Software Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | PAYC | |
|---|---|---|
Market Cap | $163.51B | $6.75B |
Sector | Health | Technology |
52-Week High | $155.80 | $238.80 |
52-Week Low | $108.22 | $113.59 |
Enterprise Value | $178.05B | $7.36B |
Dividend Yield | 2.49% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Paycom Software (PAYC) trades at $152.79, up 6.35% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $151.00. Recent earnings beat expectations in Q4 2025 and Q1 2026, with revenue growing to $2.05 billion in 2025. The company maintains strong profitability, including a 22.44% net income margin and 37.15% ROE, while launching new tools like Asset Management to drive growth.
Outlook is cautiously optimistic, with potential upside to the $183.00 high target, supported by solid fundamentals and product innovation. Risks include competitive pressures in HCM software and reliance on steady revenue growth. Investors should weigh the stock's current valuation against earnings consistency and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
